DEISSEROTH ALBERT B has a total of 16 patent applications. Its first patent ever was published in 2003. It filed its patents most often in United States, Australia and Brazil. Its main competitors in its focus markets biotechnology, pharmaceuticals and foods and drinks are PSIOXUS THERAPEUTICS LTD, VIROGIN BIOTECH CANADA LTD and PAEAN BIOTECHNOLOGY INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 9 | |
#2 | Australia | 1 | |
#3 | Brazil | 1 | |
#4 | Canada | 1 | |
#5 | China | 1 | |
#6 | Republic of Korea | 1 | |
#7 | Mexico | 1 | |
#8 | WIPO (World Intellectual Property Organization) | 1 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Pharmaceuticals | |
#3 | Foods and drinks |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Microorganisms | |
#3 | Peptides | |
#4 | Therapeutic chemical compounds | |
#5 | Enzymes |
# | Name | Total Patents |
---|---|---|
#1 | Deisseroth Albert B | 15 |
#2 | Zhang Lixin | 8 |
#3 | Chang Yucheng | 1 |
#4 | Lixin Deisseroth Albert B Zhan | 1 |
Publication | Filing date | Title |
---|---|---|
US10149899B1 | Composition and method against C-difficile | |
US9889188B1 | Ebola virus composition/vaccine | |
US2017239339A1 | Vaccine directed to induction of immune response to protein and glycolipid antigens of bacterial cells through interaction of CD4OL/CD40 receptor axis with complex of glycolipid/CD1d receptor in NKT cells and in dendritic cells | |
US10130667B1 | TAA/ecdCD40L oncolytic virus | |
US2014127252A1 | Tularemia-taa/cd40l vaccine | |
MXPA05005051A | Adenoviral vector vaccine. |